GlassScriptPhysician profile
Ryain Alexander
NPI 1508466467
$2,425.37
in general payments reported to CMS, 2019-2025
9 companies · $824 in 2025
The $824 reported for 2025 was more than what 90% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $824 · 2023: $246 · 2024: $90.08 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $1,196.70 | 2021-2023 | |
| Polynovo North America LLC | $630.62 | 2024-2025 | Novosorb Btm |
| Polymedics Innovations INC. | $161.18 | 2022-2024 | |
| Kerecis Limited | $136.30 | 2021-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Teleflex LLC | $133.59 | 2022 | |
| Merck Sharp & Dohme LLC | $103.29 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Smith+Nephew, INC. | $24.84 | 2025 | Biobrane |
| Avita Medical Americas, LLC | $19.54 | 2025 | Permeaderm, Recell, Cohealyx |
| Medela LLC | $19.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryain Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.